Opportunities and challenges of incretin-based hypoglycemic agents treating type 2 diabetes mellitus from the perspective of physiological disposition
The treatment of patients with diabetes mellitus, which is characterized by defective insulin secretion and/or the inability of tissues to respond to insulin, has been studied for decades. Many studies have focused on the use of incretin-based hypoglycemic agents in treating type 2 diabetes mellitus...
Saved in:
Main Authors: | Yaochen Xie (Author), Qian Zhou (Author), Qiaojun He (Author), Xiaoyi Wang (Author), Jincheng Wang (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2023-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Revisiting the concept of incretin and enteroendocrine L-cells as type 2 diabetes mellitus treatment
by: Kok-Hou Lok, et al.
Published: (2022) -
Efficacy and safety of hypoglycemic agents on gestational diabetes mellitus in women: A Bayesian network analysis of randomized controlled trials
by: Ting Wang, et al.
Published: (2022) -
Adherence to Oral Hypoglycemic Agents in Hawaii
by: Deborah A. Taira, ScD, et al.
Published: (2005) -
Tirzepatide - a new analogue of incretin hormones
by: Gabriela Anglart, et al.
Published: (2023) -
A Physiologically‐Based Quantitative Systems Pharmacology Model of the Incretin Hormones GLP‐1 and GIP and the DPP4 Inhibitor Sitagliptin
by: Pavel Balazki, et al.
Published: (2020)